Immunomedics’ (NASDAQ:IMMU) has halted its Phase 3 confirmatory ASCENT study due to compelling evidence of efficacy.
The remarkable results observed across multiple endpoints warranted early discontinuation of the trial.
The study evaluated sacituzumab govitecan in triple-negative breast cancer.
On another note, the company has appointed Harout
Semerjian as President and Chief Executive Officer, effective April 16.
Most recently, he served as Executive Vice President, Chief Commercial
Officer at Ipsen.
Shares are up 118% premarket.
https://seekingalpha.com/news/3558562-immunomedics-rockets-118-premarket-on-positive-adc-data-in-breast-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.